While medications such as cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine play a valuable role in managing symptoms for many people, particularly those with Alzheimer’s disease, their use often occurs within a broader context of multiple medications.
This polypharmacy, especially when it includes potentially inappropriate medicines (PIMs), raises important safety considerations.